ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 90 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2020. The put-call ratio across all filers is 0.71 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,780,800 | -36.1% | 2,871,000 | 0.0% | 0.29% | -25.1% |
| Q2 2023 | $21,561,210 | +66.2% | 2,871,000 | 0.0% | 0.39% | +53.3% |
| Q1 2023 | $12,976,920 | -59.9% | 2,871,000 | 0.0% | 0.26% | -58.8% |
| Q4 2022 | $32,356,170 | +17.8% | 2,871,000 | 0.0% | 0.62% | +21.4% |
| Q3 2022 | $27,475,000 | +55.3% | 2,871,000 | +31.3% | 0.51% | +59.4% |
| Q2 2022 | $17,687,000 | +68.3% | 2,186,269 | +251.7% | 0.32% | +88.2% |
| Q1 2022 | $10,507,000 | +135.5% | 621,700 | +199.5% | 0.17% | +198.2% |
| Q4 2021 | $4,461,000 | -59.7% | 207,600 | +38.4% | 0.06% | -53.3% |
| Q3 2021 | $11,079,000 | +35.1% | 150,000 | 0.0% | 0.12% | +47.0% |
| Q2 2021 | $8,202,000 | -25.8% | 150,000 | 0.0% | 0.08% | -19.4% |
| Q1 2021 | $11,061,000 | -14.5% | 150,000 | 0.0% | 0.10% | -8.8% |
| Q4 2020 | $12,930,000 | – | 150,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $716,436,000 | 71.38% |
| Logos Global Management LP | 3,156,981 | $233,175,000 | 16.81% |
| Vivo Capital, LLC | 4,220,048 | $311,693,000 | 14.00% |
| Cormorant Asset Management, LP | 1,012,079 | $74,752,000 | 3.04% |
| Redmile Group, LLC | 864,435 | $63,847,000 | 1.11% |
| Nan Fung Group Holdings Ltd | 41,950 | $3,098,000 | 0.99% |
| Artal Group S.A. | 500,000 | $36,930,000 | 0.83% |
| SPHERA FUNDS MANAGEMENT LTD. | 128,706 | $9,506,000 | 0.80% |
| Pier Capital, LLC | 75,362 | $5,566,000 | 0.58% |
| Financial Advisory Group | 31,417 | $2,320,000 | 0.51% |